Guardant Health Inc., a leader in precision oncology, announced the commencement of patient enrollment in the National Cancer Institute's $(NCI)$ Vanguard Study. This study evaluates Guardant Health's Shield Multi-Cancer Detection $(MCD)$ test, which is under review by the U.S. Food and Drug Administration (FDA) as part of the NCI's investigational device exemption $(IDE)$. The Vanguard Study, a critical step in cancer detection research, aims to enroll up to 24,000 participants to assess the feasibility of using MCD tests in future trials. Conducted by the Cancer Screening Research network, it seeks to determine the effectiveness of these tests in early cancer detection and reducing cancer mortality.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。